New Research In

Her2

You have access
Therapeutic targeting of HER2–CB₂R heteromers in HER2-positive breast cancer
Sandra Blasco-Benito, Estefanía Moreno, Marta Seijo-Vila, Isabel Tundidor, Clara Andradas, María M. Caffarel, Miriam Caro-Villalobos, Leyre Urigüen, Rebeca Diez-Alarcia, Gema Moreno-Bueno, Lucía Hernández, Luis Manso, Patricia Homar-Ruano, Peter J. McCormick, Lucka Bibic, Cristina Bernadó-Morales, Joaquín Arribas, Meritxell Canals, Vicent Casadó, Enric I. Canela, Manuel Guzmán, Eduardo Pérez-Gómez, and Cristina Sánchez

PNAS February 26, 2019 116 (9) 3863-3872; first published February 7, 2019. https://doi.org/10.1073/pnas.1815034116
Open Access
Increased autophagy blocks HER2-mediated breast tumorigenesis
Silvia Vega-Rubín-de-Celis, Zhongju Zou, Álvaro F. Fernández, Bo Ci, Min Kim, Guanghua Xiao, Yang Xie, and Beth Levine

PNAS April 17, 2018 115 (16) 4176-4181; first published April 2, 2018. https://doi.org/10.1073/pnas.1717800115
Open Access
ΔNp63α is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis
Linshan Hu, Shan Liang, Hu Chen, Tao Lv, Junfeng Wu, Deshi Chen, Min Wu, Shengnan Sun, Haibo Zhang, Han You, Hongbin Ji, Yujun Zhang, Johann Bergholz, and Zhi-Xiong Jim Xiao

PNAS May 16, 2017 114 (20) E3964-E3973; first published May 3, 2017. https://doi.org/10.1073/pnas.1617816114